Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for prevention of immobilization-induced bone loss in ICU patients
2018-000552-18Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of denosumab in osteoporosis, sponsored by Medical University of Vienna. Primary endpoint: Serum CTX-1 at 1 month. Started Oct 2019; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2018-000552-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000552-18.